Basal Activation of Type I Interferons (Alpha2 and Beta) and 𝟐^′𝟓^′OAS Genes: Insights into Differential Expression Profiles of Interferon System Components in Systemic Sclerosis

Table 1

Information about the subjects that consented to take part in this research.

	Sex	Age (years)	Disease time (years)^1	Treatment	ANA titer
P1	F	31	1	Prednisone	>1/320
P2	F	54	5	Methotrexate Prednisone	<1/10240
P3	M	35	5	Methotrexate Prednisone	>1/5120
P4	M	29	1	Prednisone	>1/640
P5	M	40	7	—	<1/10240
P6	F	30	2	—	>1/320
P7	F	50	5	—	>1/80
P8	M	56	6	—	<1/10240
P9	F	58	11	Methotrexate Prednisone	>1/80
P10	F	70	20	—	>1/640
C1	M	39	—	—	Not tested
C2	F	32	—	—	Not tested
C3	M	25	—	—	Not tested
C4	F	24	—	—	Not tested

C: control; P: patient; M: male; F: female; —: not treated.
¹Dated from the onset of the first non-Raynaud’s symptom.